SARA DUNCAN: Open Payments
NPI 1285108662 · CARRIERE, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$646 in 38 payments from 11 companies in 2025. Trend: 2023 $646 · 2024 $792 · 2025 $646
Food & beverage: $646
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $217 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $71 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $70 |
| Neurocrine BioSciences, Inc. | 2 | $64 |
| Corium, LLC | 3 | $61 |
| Vanda Pharmaceuticals Inc. | 3 | $55 |
| Kerecis Limited | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| PFIZER INC. | 1 | $21 |
Products named: VRAYLAR, CAPLYTA, TRINTELLIX, INGREZZA, Azstarys, FANAPT, Kerecis SurgiClose, REXULTI.
Industry payments across MS — which companies pay providers there.
